The drug discovery process can be significantly improved through understanding how the 12 structure of chemical compounds relates to their function. A common paradigm that has been 13 used to filter and prioritize compounds is ligand-based virtual screening, where large libraries of 14 compounds are queried for high structural similarity to a target molecule, with the assumption 15 that structural similarity is predictive of similar biological activity. Although the chemical 16 informatics community has already proposed a wide range of structure descriptors and similarity 17 coefficients, a major challenge has been the lack of systematic and unbiased benchmarks for 18 biological activity that covers a broad range of targets to definitively assess the performance of 19 the alternative approaches. 20
We leveraged a large set of chemical-genetic interaction data from the yeast Saccharomyces 21
cerevisiae that our labs have recently generated, covering more than 13,000 compounds from the 22 RIKEN NPDepo and several NCI, NIH, and GlaxoSmithKline (GSK) compound collections. 23 Supportive of the idea that chemical-genetic interaction data provide an unbiased proxy for 24 biological functions, we found that many commonly used structural similarity measures were 25 able to predict the compounds that exhibited similar chemical-genetic interaction profiles, 26 although these measures did exhibit significant differences in performance. Using the chemical- 27 genetic interaction profiles as a basis for our evaluation, we performed a systematic 28 benchmarking of 10 different structure descriptors, each combined with 12 different similarity 29 coefficients. We found that the All-Shortest Path (ASP) structure descriptor paired with the 30
Braun-Blanquet similarity coefficient provided superior performance that was robust across 31 several different compound collections. 32
We further describe a machine learning approach that improves the ability of the ASP metric to 33 capture biological activity. We used the ASP fingerprints as input for several supervised machine 34 learning models and the chemical-genetic interaction profiles as the standard for learning. We 35 found that the predictive power of the ASP fingerprints (as well as several other descriptors) 36 could be substantially improved by using support vector machines. For example, on held-out 37 data, we measured a 5-fold improvement in the recall of biologically similar compounds at a 38 precision of 50% based upon the ASP fingerprints. Our results generally suggest that using high-39
dimensional chemical-genetic data as a basis for refining chemical structure descriptors can be a 40 powerful approach to improving prediction of biological function from structure. 41
INTRODUCTION 44
Discovery, design, and development of new drugs that reveal desired and reproducible 45 biochemical behavior against a particular biomolecular target with minimal side effects are 46 challenging. Despite the scientific and technological advances in drug discovery during the past 47 60 years, the number of drugs approved per billion US dollars that were spent for the 48 development of novel drugs has halved roughly every 9 years since 1950 (Eroom's Law in 49 contrast to Moore's Law) [1] . Following the similar property principle (SPP) [2] , Ligand-based 50 virtual screening (LBVS) has been commonly used as an a priori step to high-throughput 51 screening (HTS) [3, 4, 5] to rank compounds of a large database in the decreasing order of their 52 similarity to a reference or target molecule with known biological activity ( Fig. 1) . According to 53 the similar property principle, structurally similar molecules are more likely to represent similar 54 biological activities and physicochemical properties. Although there are limitations to the similar 55 property principle [6] , such as the case of activity cliffs where a very small modification in the 56 structure of a molecule may drastically alter its biological properties [7] , this structure-activity 57 relationship is broadly consistent throughout the larger flat regions of activity landscapes [8, 9] . 58
Hence, the need for high performance structural similarity that extracts structurally analogous 59 compounds from a database is inevitable. 60
To accelerate the retrieval of the compounds of a desired class that are active against a 61 protein target, the chemical informatics community has suggested a wide range of structure 62 descriptors and similarity coefficients that are able to extract candidates with similar biological 63 activity from structural compound libraries. The most widely used representation of molecular 64 graphs in these expanding databases of two-and three-dimensional molecular structures is based 65 upon chemical fingerprints [10, 11, 12] , where a molecular graph is represented by a fixed-length 66 bit-vector that enumerates all the bounded-length paths in the graph and encodes the presence or 67 absence of substructural fragments. The degree of similarity of two structural vectors describing 68 two different compounds is usually measured by similarity coefficients, among which the well-69
known Tanimoto coefficient has still remained the coefficient of choice to capture the highest 70 level of intermolecular similarity and thus biological activity [11, 13] . The Tanimoto coefficient, 71
which is formulated as the number of features shared between two molecules divided by the total 72 number of features presented in both molecules, offers a suitable degree of chemical similarity 73 between compounds, although this coefficient suffers from an intrinsic bias towards selection of 74 smaller compounds [14, 15] . However, the research community has lacked a systematic 75 benchmark that assesses the performance of these structure descriptors and similarity coefficients 76 over a broad range of protein targets in an unbiased manner. 77
Chemical genomic approaches, which focus on the systematic mapping of chemical-78 genetic interactions, offer a valuable new source of data to connect structure to function. These 79 chemical-genetic maps take advantage of the massive wealth of chemical-genetic interaction 80
profiles. The yeast Saccharomyces cerevisiae is a well-characterized eukaryotic system for which 81 the genome-wide gene deletion project has identified ~5000 viable deletion mutants [16] . 82
Testing each one of these viable mutants for hypersensitivity to a bioactive compound generates 83 a chemical-genetic interaction profile in which the relative fitness of a selected group of mutant 84 strains with defined genetic perturbations in response to the bioactive compound is quantified 85 [17, 18] . These chemical-genetic interaction profiles provide functional information for a 86 compound that can be interpreted through the global genetic interaction network mapped for the 87 yeast [19] . If a bioactive compound inhibits a target protein, the loss-of-function mutations in a 88 gene that encodes the protein models the primary effects of the compound, and the genetic 89 interaction profile of the target gene resembles the chemical-genetic interaction profile of the 90 compound that inhibits the target pathway. Consequently, the chemical-genetic interaction 91 profiles of bioactive compounds can link those compounds to their cellular target pathways in an 92 unbiased manner. These profiles can be annotated to specific biological processes to predict the 93 general mechanisms of action for the bioactive compounds and can serve as an unbiased 94 genome-wide measure for their biological activity [20] . 95
We generated a systematic benchmark based upon the similar property principle to assess 96 the performance of several structure descriptors and similarity coefficients in prediction of the 97 chemical-genetic interaction profiles of hundreds of compounds, with the assumption that these 98
profiles provided an unbiased genome-wide measure of biological activity. We generated and 99 annotated the yeast chemical-genetic interaction profiles for more than 13,000 compounds from 100 the RIKEN NPDepo as well as several NCI/NIH/GSK compound collections [20] . We 101 systematically benchmarked 10 different structure descriptors, each combined with 12 different 102 similarity coefficients, to identify the pair with the superior prediction of biological activity by 103
using the chemical-genetic interaction profiles as a basis for the biological activity of our 104 compounds. We further developed several supervised machine learning models to improve our 105 prediction of the biological activity of compounds from chemical structures, gaining higher 106 predictive power that was not in the ability of similarity coefficients. We found that support 107 vector machines (SVMs) [21] can significantly enhance the power of our chemical fingerprints 108 for predicting the biological activity of compounds. 109
110
RESULTS AND DISCUSSION 111 112
To evaluate the performance of the commonly used structure descriptors and similarity 113 coefficients in predicting the biological activity of compounds, we exhaustively searched for all 114 the pairwise candidates (i.e., one structure descriptor and one similarity coefficient) that provided 115 high predictive power over a wide range of protein targets using our chemical-genetic interaction 116
data. We generated, in our labs, the chemical-genetic interaction profiles for 13,524 compounds 117 from several diverse compound collections [20] . We used a subset of these screened compounds 118 that exhibited high confidence predictions for the annotated processes and biological pathways 119 based upon our chemical-genetic interaction profiles [20, 22] . We included in our benchmarking 120 system two compound sets independently: (1) 826 compounds from the RIKEN Natural Product 121 Depository (NPDepo) compound collection, which we called RIKEN high confidence collection. 122
(2) 659 compounds from several NCI/NIH/GSK collections, which we called the NCI/NIH/GSK 123 high confidence collection (see Material). 124
Establishing a systematic benchmark for chemical similarity measures 125 126
We aimed at predicting the compound pairs that exhibited the most similar function 127 based upon our chemical-genetic interaction profiles, which served as an unbiased genome-wide 128 measure of biological activity. We labeled only 10% of the compound pairs with the highest 129
(cosine) profile similarity as our gold standard for true positives, which were highly prioritized in 130 our systematic benchmark. Following the similar property principle, a large number of these true 131 positives should be identified from the structural similarity of our compounds. 132
Our benchmarking system consisted of two main components: structure descriptors and 133 similarity coefficients. We evaluated both components through our systematic benchmark to find 134 the best performer of each component for prediction of the biological activity of our compounds. 135 We used jCompoundMapper [23] to describe all our compounds in 10 different structure spaces 136
( Table 1) , where a compound was described with a fixed-length bit-vector that indicated the 137 presence or absence of a certain number of fingerprints. The number of features required for the 138 description of the compounds in a structure space varied based upon the space definition and 139 collection properties (e.g., only 9 of the predefined features in the MACCS keys were found in 140 the RIKEN high confidence collection, while RAD2D fingerprints generated 91082 features to 141 describe this compound collection). We used 12 widely used similarity coefficients ( Table 2) to 142 measure the degree of similarity of two compounds described by a given structure descriptor. 143
Evaluating the performance of chemical similarity measures 144 145
We exhaustively searched for the best-performing chemical similarity measure (i.e., one 146 structure descriptor and one similarity coefficient) in predicting the biological activity of our 147 compounds. We described all our compounds in 10 different structure spaces and measured the 148 structural similarity of two compounds described in a given structure space by using a coefficient 149 of structural similarity, generating compound similarities for all the combinations of structure 150 descriptors and similarity coefficients. We ranked all these scores of structural similarity for the 151 prediction of the chemical-genetic profile similarity of our compounds and measured precision at 152 many recalls to evaluate the performance of alternative models (Suppl. Table 1 ). To isolate the 153 winning structure descriptor, we looked at the precision of all the prediction models at several 154 (lower) recalls for our RIKEN high confidence collection, which distinguished ASP, LSTAR, 155 and RAD2D fingerprints as the structure descriptors with superior predictive power ( Fig. 2a) . 156 The wide range of precision values achieved by different structure descriptors, assuming that a 157 single similarity coefficient was used, showed that our chemical-genetic interaction profiles 158 could highly separate structure descriptors in terms of their efficiency for the prediction of the 159 biological activity of compounds. We compared the relative performance of our distinguished 160 models with the predictive power of extended-connectivity fingerprints (ECFP) [24] , which has 161 recently been one of the most common descriptors to represent molecular graphs. However, 162
ECFP did not generally outperform ASP, LSTAR, and RAD2D fingerprints, except at very few 163 recalls ( Fig. 2b) . Because this finding might simply be a result of our collection property, we 164 used our NCI/NIH/GSK high confidence collection to validate the predictive performance of the 165 ASP, LSTAR, and RAD2D fingerprints, which strongly confirmed the superiority of these 166 descriptors over ECFP at many recalls ( Fig. 3) . 167 ASP fingerprints encoded a graph traversal over all atoms in a molecular graph but stored 168 only the shortest paths between atoms, whereas LSTAR and RAD2D fingerprints described the 169 radial environment of all atoms in the molecular graph [23] . As a result, the ASP encoding that 170 described our compound collections needed fewer features than LSTAR and RAD2D encodings 171
( Table 1) although the predictive performance of the ASP fingerprints was higher or comparable 172 with that of LSTAR and RAD2D fingerprints at several recalls. Moreover, LSTAR fingerprints 173 generally exhibited higher performance than RAD2D fingerprints at several recalls ( Figs. 2-3) , 174 which could be justified by additional information that LSTAR fingerprints collected from the 175 radial environment of the atoms by definition. Therefore, we determined ASP and LSTAR 176 fingerprints as the winning structure descriptors to describe compounds and predict the ones with 177 the highest biological similarity to a target molecule using a similarity coefficient. 178
We systematically benchmarked 12 similarity coefficients ( Table 2 ) by using our RIKEN 179 high confidence collection and measured the predictive performance of every coefficient over all 180 structure descriptors to find the winning similarity coefficient. We found that several (8 out of 181 12) coefficients were able to exhibit consistent high performance across all structure descriptors, 182 although 4 similarity coefficients (Asymmetric, Russel/Rao, Euclidean, and Dot-product) failed 183 in some structure descriptor spaces because their precision significantly dropped at lower recalls. 184
In other words, precision of several models (each corresponding to one structure descriptor) was 185 substantially low for each of these 4 similarity coefficients at many lower recalls (Suppl . Table  186 1), which indicated that these 4 coefficients were unable to predict the biological similarity of 187 our compounds across different structure descriptors consistently. We, as a result, removed these 188 4 coefficients from our analysis and focused only on 8 remaining similarity coefficients. We 189 found that the Braun-Blanquet similarity coefficient [25] resulted in the higher precision at many 190 recalls compared to all other coefficients, including Tanimoto and cosine coefficients ( Fig. 2a) , 191 which have been widely used by the chemical informatics community. For the Braun-Blanquet 192 similarity coefficient, the average precision and the average area under the receiver operating 193 characteristic (ROC) curves across all structure descriptors were slightly higher at many recalls 194 compared to those of the Tanimoto and cosine coefficients ( Fig. 2a ; columnar green values), 195
suggesting that this simple coefficient of structural similarity could confidently be used in place 196 of the traditional Tanimoto coefficient for the ranking of database compounds in the decreasing 197 order of biological similarity to a target molecule. The Braun-Blanquet coefficient, which was 198 simply formulated as the number of features common between two molecules divided by the 199 total number of features presented by the larger molecule, determined the degree of contribution 200 of the smaller molecular graph to the larger one. We further measured the performance of our 201 predictive models using our NCI/NIH/GSK high confidence collection to validate the superiority 202 of the Braun-Blanquet coefficient over other similarity coefficients ( Fig. 3a and Suppl. Table 2) . 203 We, therefore, paired the Braun-Blanquet similarity coefficient with the ASP and LSTAR 204 structure descriptors as our predictive models for ligand-based virtual screening. 205
Optimizing the depth of structure descriptors 206 207
One major parameter involved in the structural description of compound collections was 208 the describing depth; a high depth generated numerous features to cover the global environment 209 of each atom, whereas a low depth only focused on describing the local neighborhood of atoms 210 in the molecular graph. We assessed the impact of the depth of 5 structure descriptors (ASP, DFS, 211 ECFP, LSTAR, and RAD2D) in predicting the biological activity of our compounds using the 212
Braun-Blanquet similarity coefficient ( Fig. 4) . Describing our RIEKN high confidence collection 213 at a high depth generally resulted in strong predictions at lower recalls but moderate outcome at 214 higher recalls because a high depth was able to predict the compound pairs that were structurally 215 and therefore functionally very similar according to the similar property principle (SPP) but also 216 pushed undesired pairs such as activity cliffs to the top of our predictions. On the other hand, a 217 low describing depth was able to capture the similarity of two compounds in the local chunks of 218 the two molecular graphs that were essential for functional similarity, which eventually resulted 219 in drawing reasonable predictions at lower recalls. We, furthermore, evaluated these results using 220
our NCI/NIH/GSK high confidence collection (Suppl. Fig. 1 ), which confirmed similar general 221 trends that impacted our predictions at several recalls using 10 different describing depths. 222
Therefore, the structural description of a compound collection at high depths not only was 223 unnecessary and inefficient but also increased the computation time and space complexity. We 224 selected depth 8 for our evaluations although other neighboring depths were also justifiable. 225
Improving the prediction performance via SVM models 226 227
To increase the ability of chemical structures in predicting the biological activity of our 228 compounds, we designed several supervised machine learning models and took advantage of the 229 great wealth of chemical-genetic interaction maps for supervision. Moreover, we used supervised 230 principal component analysis [26] via chemical-genetic interaction maps to extract a number of 231 features from the more informative compound substructures that highly related structural data to 232 the biological activity of our compounds. We found that support vector regression (SVR) models 233
[21] were able to boost the prediction performance of the functional activity of our compounds 234 from their chemical structures by weighting supervised principal components, where chemical-235 genetic interaction profiles were also input to the learning models for supervision. 236 237
We designed a learning pipeline ( Fig. 5a) to predict chemical-genetic profile similarities 238 by creating bootstraps [27] and pairwise structural encodings (see Methods). We implemented 239 support vector regression models in LibSVM [28] , a popular open source support vector machine 240 learning library developed at National Taiwan University, and used Radial Basis Function (RBF) 241 kernels for building our epsilon support vector regression models. We developed precision-recall 242 (PR) curves to evaluate the performance of our models for different structure descriptors, where 243 only 10% of the compound pairs from our RIKEN high confidence collection with the highest 244 chemical-genetic profile similarity were labeled as the gold standard for true positives. We found 245 that a subset of our structure descriptors (SD1-SD6 and SD10) were able to achieve significantly 246 higher performance in the prediction of the functional similarity of our compounds than the best-247 performing chemical similarity measures (i.e., ASP or LSTAR fingerprints along with the Braun-248
Blanquet similarity coefficient). The learning curves for the ASP and LSTAR fingerprints ( Fig.  249 5b) exhibited that we were able to gain a 5-fold improvement in the recall of biologically similar 250 compounds at a precision of 50%. However, the degree of improvement was dependent on the 251 functional diversity of datasets, which could result in modestly higher performance for particular 252 collections with higher diversity; for instance, we improved our predictions for the 253 NCI/NIH/GSK high confidence collection by only about 2 folds in the recall of biologically 254 similar compounds at a precision of 50% ( Fig. 5d-e ). This relatively poor improvement 255
(compared to that of the RIKEN high confidence collection) was explained by the higher 256 functional diversity of our NCI/NIH/GSK high confidence collection (score of ~25.3, against 257 ~14.6 for the RIKEN high confidence collection) although the two collections exhibited similar 258 structural diversity (score of ~62) (see Methods). This high functional diversity of the 259 NCI/NIH/GSK high confidence collection was due to the presence of 6 functionally different 260 sub-collections, which consequently affected the ability of our models to learn chemical-genetic 261 similarities at a high performance for this collection. Although model performance was disturbed 262 by the higher diversity of our NCI/NIH/GSK high confidence collection, we still measured more 263 distinct learning curves from the baseline while labeling 20% of functionally most similar 264 compound pairs as true positives (Fig. 5e) , indicating that functionally similar pairs were 265 eventually pushed up to the top of the ranked lists by our learning models. Furthermore, we 266 combined the two collections, which added not only more diversity but also more compounds to 267 the RIKEN high confidence collection, and made predictions for the combined dataset, resulting 268 in about a 4.5-fold improvement in the recall of biologically similar compounds at the precision 269 of 50% (Fig. 5c) . To accomplish higher prediction performance, we, therefore, would need a 270 larger training set (compounds with known chemical-genetic interaction profiles) to compensate 271 for the high functional diversity of compound collections and facilitate the learning process. 272 273
Predictive power of structural similarity and SVM models 274 275
To investigate the compounds driving our prediction models and the underlying function, 276
we clustered our compound collections into 10 functional as well as 10 structural clusters using 277 K-means and K-medoids, respectively, and mapped only the true positives at the top of our PR 278 curves to their corresponding functional and structural clusters ( Fig. 6) . We found that a large 279 group of compounds generating high prediction scores at the top of our learning curves belonged 280 to the same functional clusters (Fig. 6b) , whereas the baseline curve for the ASP fingerprints and 281
Braun-Blanquet similarity coefficient included several functional clusters even at lower recalls 282 (Fig. 6c) . Therefore, our learning models placed more emphasis on the learning of a few certain 283 functional clusters and boosted our prediction performance for those clusters. The first functional 284 cluster that appeared on the learning curve of ASP fingerprints for the RIKEN high confidence 285
collection (blue bar in Fig. 6b ) was enriched for cell cycle processes based upon the predictions 286
at the MOSAIC database [29] (Suppl. Tables 3-4 for enrichment of functional clusters). Despite 287 this functional tendency that the learning models showed, several structural clusters contributed 288
to the predicted pairs with high scores for the learning models ( Fig. 6e) , which could lead us to 289 discovering structurally diverse compounds that would exhibit similar biological activities. The 290 discovery of such compounds was of crucial importance since exploring functional analogs with 291 dissimilar structures was entirely out of the capacity of the similar property principle. Hence, our 292 learning models were able to extract compounds with similar function but distinct structures for a 293 target drug/compound, which was far beyond the scope of structural similarity coefficients. For 294
instance, our learning model for the RIKEN high confidence collection assigned a high score to 295 the biologically similar compounds NPD2186 and NPD3120 (chemical-genetic profile similarity 296 of 0.862), while the Braun-Blanquet similarity coefficient for this pair was as low as 0.027 ( Fig.  297 8c; Suppl. Table 5 ). This property of our learning models was achieved by design, where we 298 extracted only a subset of the supervised principal components that were significantly related to 299 the biological activity of compounds, and we then weighted this subset of supervised principal 300 components using support vector regression models. This model property existed in our learning 301 models for the NCI/NIH/GSK high confidence collection as well but in a weaker manner due to 302 the high functional diversity of this collection ( Fig. 7 and Fig. 8d ). 303 304
Furthermore, we assessed the predictive power of structural similarity (using the Braun-305
Blanquet coefficient) against that of chemical-genetic profile similarity for our collections. For 306 the former, we predicted the chemical-genetic profile similarity of our compounds from chemical 307 structures, whereas, for the latter, we used the chemical-genetic profile similarity of compounds 308
to predict their structural similarity. The PR curves revealed that the structural similarity of our 309 compounds had higher predictive power of the chemical-genetic similarity than the latter of the 310 former ( Fig. 8a-b ) since compounds with similar biological activity could represent completely 311 different chemical structures. On the other hand, compounds with similar structures were highly 312 expected to exhibit similar biological activity; therefore, our results were a strong confirmation 313 for the similar property principle. Moreover, the degree of superiority of the predictive power of 314 structural similarity over functional similarity was an indicator of the amount of substructures 315 (i.e., compounds with similar biological activity but distinct structures) that existed in the 316 collection. The wide gap between the curves for the RIKEN high confidence collection (Fig. 8a) , 317 therefore, represented a large number of substructures in this collection (see Fig. 6 ), while the 318 narrow gap between the curves for the NCI/NIH/GSK high confidence collection (Fig. 8b ) 319 served as a signal that this collection, which was composed of several sub-collections, included 320 more of one-to-one correspondence between structural and functional profiles. Since the high 321 power of our learning models was to discover compounds of various structures (in addition to 322 compounds with similar structures) that exhibited similar biological activity to a target 323 drug/compound, our learning method showed enormous superiority over the baseline approach 324
(ASP fingerprints paired with the Braun-Blanquet similarity coefficient) for our RIKEN high 325 confidence collection. Although our learning method improved predictions for the functionally 326
diverse collections (such as our NCI/NIH/GSK high confidence collection) moderately, this 327 method exhibited strong predictions for the larger collections representing certain biological 328 functions with structurally diverse compounds. 329
330
CONCLUSION 331 332
The chemical informatics community has adopted a broad range of structure descriptors 333 and similarity coefficients for ligand-based virtual screening where the similar property principle 334 has been the basis for ranking of compounds with similar biological activity to a target molecule 335 from chemical structures. However, the research community has lacked a systematic, unbiased 336 benchmark for biological activity that would cover a wide range of targets to definitively assess 337 the performance of alternatives. We generated chemical-genetic interaction profiles from yeast in 338 our labs, covering 13,431 compounds from the RIKEN NPDepo and several NCI/NIH/GSK 339 compound collections, and used these profiles as an unbiased standard for the biological activity 340 of our compounds. Using these chemical-genetic interaction profiles as the basis for the function 341 of our compounds, we systematically benchmarked 10 different structure descriptors and 12 342 different similarity coefficients. We found that the ASP (and LSTAR) fingerprints paired with 343 the Braun-Blanquet similarity coefficient revealed as the superior choice for ranking of 344 compounds with similar biological activity to a target molecule. The ASP fingerprints encoded 345 all shortest paths between atoms obtained through an exhaustive depth-first search of the 346 molecular graph (up to a predefined depth), and the Braun-Blanquet coefficient represented the 347 number of features shared between two molecules divided by the number of features presented in 348 the larger one. Moreover, we devised a machine learning model that boosted the predictive 349 power of several fingerprints, although the degree of improvement was correlated to the 350 functional diversity of our compound collections. We found that structural similarity had a 351 higher predictive power in prediction of functional similarity than the latter of the former 352 because several substructures contributed to the similar biological activity. Although similarity 353 coefficients predicted the compounds that had both similar function and similar structure, our 354 learning models assigned higher predictive scores to most compounds with similar function by 355
weighting the supervised principal components that were strongly correlated to the chemical-356 genetic profiles. Therefore, our learning models were able to predict compounds from a library 357 with similar biological activity but diverse structures to a target molecule, which significantly 358 improved performance relative to simple similarity coefficients applied to structure descriptors. 359
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We Designing the support vector machine learning pipeline 384 385
We proposed support vector regression (SVR) models for the prediction of the functional 386 activity of our compounds based upon their chemical structures. We used LibSVM [28] for the 387 implementation of our models and bootstrapping [27] for generating our training and test sets. To 388 generate these training and test sets, we drew N (the total number of compounds in a collection) 389 samples uniformly random from the collection but with replacement, assigning ~0.632N unique 390 compounds to the training and the rest to the test set. We used supervised principal component 391 analysis [26] with adaption of chemical-genetic interaction profiles, assuming that these profiles 392
were known for the training set but unknown for the test set, to lower the dimension of structure 393 spaces. We normalized each structural vector that described a compound in the low-dimensional 394 space by its Euclidean length and multiplied each pair of the normalized vectors (both from the 395 training set or both from the test set) in the element-wise manner to create a new structure space, 396 called "pairwise structural encodings", for the representation of compound pairs (Suppl. Fig.  397   2a) . We devised a pipeline (Fig. 5a) to predict our chemical-genetic profile similarities by using 398 pairwise structural encodings, feeding our regression models with pairwise structural 399 vectors and chemical-genetic profile similarities, where m was the number of compounds in the 400 training set, to predict the chemical-genetic profile similarities for the compound 401
pairs that were corresponding to the test set. We used Radial Basis Function (RBF) kernels to 402 build up epsilon support vector regression models and input a number of bootstraps to the 403 models to evaluate the average performance of our models across all bootstraps (Suppl. Fig. 2b) . 404 To measure the prediction of our pipeline for a newly seen input, we needed to take the average 405 over all the model outputs resulted from different bootstraps, where the new input was treated as 406 a test data in the test sets; the higher the number of bootstraps the more accurate the prediction 407 value. We generated a large number of bootstraps (200 bootstraps for the RIKEN and 408 NCI/NIH/GSK high confidence collections as well as 100 bootstraps for the combined 409 collection) for our evaluations although the performance of our learning models was constant 410
after meeting a certain number of bootstraps. 411 412
Estimating the diversity of compound collections 413 414
We assigned all the compounds in a collection to a single cluster and split up the cluster 415 recursively to form clusters of more similar compounds. At any step of recursion, we determined 416 the cluster with the lowest average within-cluster chemical-genetic profile similarity (to compute 417 the functional diversity) or structural similarity (to compute the structural diversity) and divided 418 the cluster into two new clusters using K-means or K-medoids clustering. We stopped generating 419 new clusters right before our algorithm would generate at least two individual clusters exceeding 420 our predefined hard limit for the maximum average between-cluster chemical-genetic similarity 421
(cosine similarity of 0.3) or structural similarity (Braun-Blanquet similarity of 0.3). We repeated 422 the algorithm many times (1000 times for the functional diversity and 100 times for the structural 423 diversity) and computed the mean diversity score as the average exponentiation of the Shannon 424 entropy indices over all the instances: 425 All the compounds of the MOSAIC database (http://mosaic.cs.umn.edu) [29] were ranked in the 436 decreasing order of structural similarity to the target molecule based upon the similar property 437 principle (SPP). In this ranked list, NPD4974 had a very distinct chemical-genetic profile from 438 NPD2186, appearing as a false positive generated by SPP. Here, we described all the compounds 439 using ASP fingerprints (depth 8) and measured the structural similarity using the Braun-Blanquet 440 similarity coefficient. 441 442 using the (a) RIKEN and (b) NCI/NIH/GSK high confidence collections, we measured that 492 structural similarity showed higher predictive power of chemical-genetic profile similarity than 493 the latter of the former largely because of substructures. Our learning models extracted 494 biologically similar but structurally very dissimilar compounds for (c) NPD2186 from our 495 RIKEN high confidence collection and for (d) NSC745750 from our NCI/NIH/GSK high 496 confidence collection. 497 498
Suppl. Figure 1. Depth impact of structure descriptors on the performance of prediction 499 models. We measured the precision of our prediction models at 10 consequent molecular depths 500 for 5 different structure descriptors, each paired with the Braun-Blanquet similarity coefficient, 501 using our NCI/NIH/GSK high confidence collection. 502 503
Suppl. profile similarity of the test pairs (represented by "X") was predicted, and all the predicted values 508 for a test pair at different bootstraps were averaged to smoothen the prediction. were collected by Raymond and Willett [12] ) for measurement of the degree of similarity of two 520 compounds described by a given fingerprint-based structure descriptor. Here, x = number of bits 521 set in both fingerprints, y = number of bits set in the first fingerprint, z = number of bits set in the 522 second fingerprint, and w = number of bits in the bit string. For the Tullos similarity coefficient, 523 (2) . 524
525
Suppl. Table 1 . Precision at several recalls for all combinations of structure descriptors and 526 similarity coefficients using our RIKEN high confidence collection. 527 528
Suppl. Table 2 . Precision at several recalls for all combinations of structure descriptors and 529 similarity coefficients using our NCI/NIH/GSK high confidence collection. 530 531
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